Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
  • Home
  • ICR Divisions
  • Radiotherapy and Imaging
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.

Thumbnail
Date
2011-10
ICR Author
Huddart, Robert
Author
Warde, P
Huddart, R
Bolton, D
Heidenreich, A
Gilligan, T
Fossa, S
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
The treatment of patients with Stage I-II seminoma has changed considerably in the past decade, and in November 2009, an International Consensus meeting was held under the sponsorship of the Union for International Cancer Control (UICC), Société Internationale d'Urologie (SIU), and International Consultation on Urological Diseases (ICUD) to review recent updates in the published data and develop international consensus guidelines on the treatment of this group of patients. In Stage I disease, the consensus conference recommended that patients should be informed of all treatment options, including the potential benefits and side effects of each treatment. It was agreed that this discussion should include a review of the possible salvage treatment effects. In addition, in patients willing and able to adhere to a surveillance program, this should be considered the management option of choice (assuming facilities are available for suitable monitoring). For Stage IIA disease, the consensus conference recommended that radiotherapy should be considered the standard treatment in the absence of contraindications. For Stage IIB disease, chemotherapy or radiotherapy were considered reasonable treatment approaches, and for Stage IIC disease, chemotherapy should be considered the standard treatment approach. For patients with a residual mass after chemotherapy, the consensus conference noted that patients with masses <3 cm in diameter could likely be safely observed, and patients with residual masses >3 cm in diameter could be considered for immediate surgery or close observation. It was also noted that surgery in this setting is technically challenging and could be associated with greater morbidity than in patients with nonseminomatous tumors.
URI
https://repository.icr.ac.uk/handle/internal/2127
DOI
https://doi.org/10.1016/j.urology.2011.02.031
Collections
  • Radiotherapy and Imaging
Subject
Humans
Seminoma
Testicular Neoplasms
Neoplasm Staging
Combined Modality Therapy
China
Male
Practice Guidelines as Topic
Research team
Clinical Academic Radiotherapy (Huddart)
Language
eng
Date accepted
2011-02-14
License start date
2011-10
Citation
Urology, 2011, 78 (4 Suppl), pp. S435 - S443

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.